title: "Retatrutide vs Semaglutide vs Tirzepatide: Which Is Better?" slug: retatrutide-vs-semaglutide path: /peptides/retatrutide-vs-semaglutide canonical_url: https://www.middlewaynutrition.com/peptides/retatrutide-vs-semaglutide status: draft author_id: 7d6125ab-eae2-4fb9-b689-9b228c17788f published_at: 2026-03-25T08:00:00Z categories: [peptides, weight-loss]

Retatrutide vs Semaglutide vs Tirzepatide: Which Is Better?

Retatrutide produces more weight loss than semaglutide or tirzepatide — 24.2% vs 14.9% vs 22.5% in clinical trials. The trade-off is that retatrutide isn't FDA-approved yet and carries more side effects due to its triple-agonist mechanism.

The Head-to-Head Comparison

Retatrutide vs Semaglutide: A Detailed Look

Semaglutide was the gold standard for GLP-1 weight loss for years. Retatrutide makes it look underpowered.

Mechanism: Semaglutide hits one receptor — GLP-1. It slows gastric emptying, suppresses appetite centrally, and drives glucose-dependent insulin release. That single-receptor approach produces consistent, predictable results. Retatrutide hits three: GLP-1, GIP, and glucagon. The glucagon piece is what separates it from everything else on this list — glucagon receptor activation ramps up hepatic fat oxidation and increases resting energy expenditure, pushing fat loss beyond what appetite suppression alone can achieve.

Weight loss numbers: In the STEP-1 trial (2021, N=1,961, 68 weeks), semaglutide 2.4mg produced mean weight loss of 14.9%. In the TRIUMPH Phase 2 trial (2023, N=338, 48 weeks), retatrutide 12mg produced 24.2% — that's a ~10 percentage point gap, achieved in 20 fewer weeks. At the 8mg dose, retatrutide still hit 22.8%.

Dosing schedules:

Side effects: Both cause the same GI discomfort — nausea, vomiting, diarrhea, constipation. Retatrutide adds a glucagon-driven effect: heart rate increases of around 3–5 bpm are common. Semaglutide's side effect profile is better understood because it's been used clinically for nearly a decade.

Cardiovascular data: This is semaglutide's strongest card. The SELECT trial showed a 20% reduction in MACE (major adverse cardiovascular events) in patients with pre-existing cardiovascular disease. Retatrutide has no CV outcome data yet — those trials are ongoing.

Bottom line on this matchup: If you want maximum fat loss and are comfortable with the fact that long-term safety data is still being collected, retatrutide wins on efficacy. If you want proven cardiovascular protection and wide insurance coverage, semaglutide is still the right call.

Retatrutide vs Tirzepatide: Closer Than You Think

This is the more interesting comparison. Both are Eli Lilly molecules. Both hit GLP-1 and GIP. Retatrutide just adds glucagon on top.

Mechanism: Tirzepatide (Zepbound for obesity, Mounjaro for diabetes) is a dual GIP/GLP-1 agonist. The GIP component improves insulin sensitivity and influences fat metabolism in ways that amplify GLP-1's appetite suppression. That synergy is why tirzepatide outperformed semaglutide so decisively. Retatrutide's glucagon receptor addition is designed to push energy expenditure higher still, targeting metabolic rate rather than just appetite.

Weight loss numbers: SURMOUNT-1 (2022, N=2,539, 72 weeks) showed tirzepatide 15mg achieving 22.5% mean weight reduction. The TRIUMPH Phase 2 trial put retatrutide at 24.2% in 48 weeks at 12mg. The gap narrows significantly when you account for the shorter trial duration — retatrutide matched tirzepatide's results faster.

Dosing schedules:

Side effects: Very similar profiles. Both cause nausea during titration, constipation, and injection site reactions. Retatrutide's glucagon component adds the heart rate elevation and may cause more pronounced early GI symptoms.

Liver fat: Both show significant hepatic fat reduction — a major benefit for people with NAFLD/MASH. Retatrutide's glucagon receptor activation appears to drive this more aggressively: Phase 2 data showed ~50% liver fat reduction vs tirzepatide's ~44% in comparable studies.

FDA status: Tirzepatide is fully FDA-approved for obesity (Zepbound, 2023) and available now. Retatrutide remains investigational.

Bottom line on this matchup: Tirzepatide is available today, FDA-approved, and comes within 2 percentage points of retatrutide's best trial number. For most people, tirzepatide is the practical choice right now. Retatrutide makes sense if you're trying to maximize results and willing to access it through compounding while Phase 3 data matures.

What About Cagrisema and Survodutide?

Two other molecules worth knowing about:

CagriSema is Novo Nordisk's combination of semaglutide + cagrilintide (an amylin analogue). Phase 3 REDEFINE trials showed ~22.7% weight loss at 68 weeks — competitive with tirzepatide and approaching retatrutide. CagriSema takes a different approach: instead of adding more receptor targets, it combines GLP-1 with amylin signaling to hit satiety from two angles. Still in late-stage trials.

Survodutide (BI 456906) is a GLP-1/glucagon dual agonist from Boehringer Ingelheim. Early trials showed strong liver fat reduction (relevant for MASH/NASH) and solid weight loss (~14–18% range in Phase 2). It's specifically being developed for metabolic-associated steatohepatitis (MASH) as well as obesity. Less weight loss than retatrutide but with a specific hepatic indication.

Mazdutide (IBI362) is a GLP-1/glucagon dual agonist from Innovent Biologics, primarily studied in Chinese populations. Phase 2 data shows weight loss in the 12–14% range. It's not in large-scale Western trials and isn't on the near-term US/EU market.

The pattern: as more receptor targets are engaged (or as complementary mechanisms are stacked), weight loss outcomes improve. Retatrutide currently sits at the top of that hierarchy.

Clinical Trial Data at a Glance

Note: These are separate trials with different populations, baselines, and designs. No head-to-head study has directly compared all five compounds in the same trial.

Who Should Consider Each Option

Choose semaglutide if:

• You want FDA-approved, widely covered by insurance
• You have cardiovascular disease and want proven MACE risk reduction (SELECT trial data)
• You prefer the option of an oral form (Rybelsus, though less effective than injectable)
• You want the most extensive real-world safety dataset available

Choose tirzepatide if:

• You want maximum weight loss from an FDA-approved drug available today
• Your insurer covers Zepbound or you're accessing compounded tirzepatide
• You have type 2 diabetes — Mounjaro is also FDA-approved for T2D with strong HbA1c reductions
• You want a well-studied option that's close to retatrutide's efficacy without the wait

Choose retatrutide if:

• You want the highest weight loss potential in the shortest timeframe
• You have significant liver fat or metabolic liver disease
• You've plateaued on semaglutide or tirzepatide and want to step up
• You're comfortable accessing it via compounding while Phase 3 data is finalized
• You don't have existing cardiovascular disease (where semaglutide's SELECT data becomes less critical)

Consider cagrisema/survodutide if:

• You specifically have MASH/NAFLD (survodutide)
• You respond well to semaglutide but want to push results further without switching to a triple agonist (cagrisema)

Side Effects: What to Expect

All three drugs share a common side effect profile driven by their GLP-1 activity:

Retatrutide's heart rate increase is a real consideration, especially if you have pre-existing cardiac conditions. The glucagon receptor activation drives this effect — it typically stabilizes after the first few weeks at each dose level.

For a complete breakdown of retatrutide-specific side effects and how to manage them, see the retatrutide side effects guide.

Retatrutide Dosing Deep Dive

See the full retatrutide dosage guide →

The TRIUMPH Phase 2 trial used a 4-step escalation protocol. Most users following compounded retatrutide protocols use a modified version:

Slower titration reduces GI side effects. There's no requirement to reach 12mg — many users achieve substantial results at 8mg.

For a full explanation of what retatrutide is and how it works, including mechanism diagrams and receptor binding data, see the dedicated guide.

Where to Get Retatrutide

Retatrutide isn't FDA-approved, which means it's not available through traditional pharmacies. It's currently accessible through licensed compounding pharmacies in the US.

The Verdict: Which Is Better?

There's no single right answer — it depends on what you're optimizing for.

Pure weight loss efficacy: Retatrutide leads. 24.2% in 48 weeks beats everything else in clinical trials.

Best option available today: Tirzepatide. FDA-approved, close to retatrutide's efficacy, accessible through standard pharmacies or compounding.

Best safety and CV data: Semaglutide. The SELECT trial cardiovascular outcome data is genuinely differentiated and matters if you have existing heart disease.

Best for liver disease: Retatrutide's glucagon receptor activation produces the largest liver fat reductions seen in any weight loss peptide trial.

The trajectory is clear: triple agonism outperforms dual, which outperforms single. Each additional mechanism adds meaningful weight loss. Retatrutide is the current ceiling of that progression, with more receptor targets still being investigated in preclinical research.

For a deeper look at what retatrutide is, how it was developed, and what the full Phase 3 data will tell us, read the complete retatrutide guide.